Healthcare's Valuation Disconnect Signals Opportunity for Asia's Wealth Allocators
The healthcare sector is currently trading at a discount to the broader market, presenting a compelling opportunity for wealth allocators in Asia. This article explores the reasons behind this disconnect and the potential benefits for investors.
A Sector in Distress, But Not Without Merit
Healthcare has been a challenging sector for investors over the past two years, with political uncertainty in the United States and rising interest rates impacting its performance. However, beneath the surface, the sector's fundamentals remain strong.
Marcel Fritsch, Head of Healthcare Funds and Mandates at Bellevue Asset Management, highlights the sector's resilience. He notes that underlying earnings quality and revenue growth across most sub-sectors are intact, despite the sector's poor performance. The resolution of the most-favored-nation pricing dispute with the US government has removed a significant political overhang, stabilizing the sector.
Small and mid-cap biotech companies have performed well due to strong clinical results and increased acquisition activity from large pharma firms. Healthcare providers, particularly US health insurance companies, have also shown signs of improvement, with first-quarter 2026 results indicating that premiums are high enough to cover medical costs.
The Valuation Opportunity
The current valuation disconnect is particularly striking. The MSCI World Healthcare Index trades at around 17 times forward earnings, compared to approximately 21 times for the S&P 500. This represents a significant discount to the long-term average, making it an attractive entry point for investors.
Diya Lowe, Head of Distribution for Asia Pacific at Bellevue Asset Management, emphasizes the opportunity this presents. She believes that the fundamentals of healthcare companies remain strong, and the current valuations offer investors a chance to build exposure at attractive levels.
Innovation as the Growth Engine
Innovation is a key driver of long-term growth in healthcare. Fritsch highlights several areas where new products and treatment modalities are creating new revenue streams.
In cardiovascular medicine, lipoprotein(a) (Lp(a)) represents a large untapped opportunity. Elevated levels of Lp(a) affect approximately one in five people and cannot be managed through diet or exercise. Several companies are developing therapies for this condition, with late-stage trials expected in 2026.
Medtech innovation is also creating new markets. Robotic surgery, for example, is advancing with AI-driven features, and continuous glucose monitoring is expected to grow significantly in the coming years.
AI as an Enabler, Not a Disruptor
Artificial intelligence (AI) is often seen as a disruptive force, but Fritsch argues that it primarily acts as an efficiency tool in healthcare. In pharma and biotech, AI accelerates drug development, improves patient selection for clinical trials, and predicts toxicity profiles, potentially saving billions in costs.
For health insurance companies, AI automates invoice processing and contract management. In medtech, heavy regulation creates natural barriers to software disruption, giving hardware-based businesses a head start in adopting AI.
M&A as a Structural Imperative
Patent expirations pose a significant risk to big pharma, with potential revenue losses in the hundreds of billions of dollars. Fritsch believes that mergers and acquisitions (M&A) are necessary to address this challenge.
The 20 largest biopharma companies collectively hold over $1 trillion in cash and debt capacity, enabling them to pursue major transactions. M&A activity is accelerating, with deals like Boston Scientific's acquisition of Penumbra and Danaher's purchase of Masimo.
Building the Case for Allocation
Healthcare remains structurally underweight in most portfolios, despite its defensive qualities and innovation-driven growth. Wealth managers and family office professionals are increasingly recognizing the sector's potential as a complement to concentrated technology positions.
Lowe notes that the current dislocation in healthcare valuations represents a window of opportunity for disciplined allocators. As investors reevaluate their portfolios, healthcare's undervaluation and strong fundamentals make it an attractive sector to consider.
Bellevue Asset Management, with its expertise in healthcare equities and a focus on innovation, positions itself as a specialist partner for investors seeking differentiated exposure. The firm's vehicles cover broad healthcare, medtech, and emerging markets healthcare, making it a valuable resource for wealth allocators in Asia.
